# Search log / 检索日志

## 1. Scope / 范围

This log records every query, tool attempt and outcome behind the repository, including failures and refusals, so that absence claims in the documents can be traced to a query ID. It also lists the unmapped claims, the topics that returned nothing, the claims to verify first and the leads for a second search round.

> 本日志记录仓库背后的每次查询、工具尝试和结果，包括失败和拒绝，使文档中的“缺失”论断都能追溯到查询 ID。它还列出无法映射的主张、没有返回任何结果的主题、需要优先核验的主张，以及第二轮检索的线索。

## 2. Legend and totals / 图例与总数

Mode E is the extended web search and mode S is the standard web search. "EMPTY" means the target topic returned no relevant hits. In total, 34 extended and 5 standard searches completed, 2 more were interrupted by the user and re-run in modified form, and 3 non-search attempts failed or were blocked: two page fetches that could not resolve their hosts and one shell command blocked by the permission classifier.

> 模式 E 是扩展网络检索，模式 S 是标准网络检索。“EMPTY”表示目标主题没有返回相关命中。总计完成 34 次扩展检索和 5 次标准检索，另有 2 次被用户中断并以改写形式重跑，还有 3 次非检索尝试失败或被拦截：两次因无法解析主机而失败的页面抓取，以及一条被权限分类器拦截的 shell 命令。

## 3. Log / 日志

<!-- search-table:start -->
| ID | Mode | Query or attempt | Outcome | 结果（中文） |
|---|---|---|---|---|
| Q01 | E | genetic variation drug target affects drug-induced transcriptional response response-eQTL | ok | 正常 |
| Q02 | E | world model architecture virtual cell transcriptome perturbation prediction 2025 2026 | ok | 正常 |
| Q03 | E | Arc Institute Virtual Cell Challenge 2025 results STATE model Tahoe-100M | ok; STATE ranking and Tahoe results in the challenge not found | 正常；挑战赛中 STATE 排名和 Tahoe 结果未找到 |
| Q04 | E | single-cell eQTL context-specific dynamic eQTL drug stimulation sc-eQTLGen consortium | drug-stimulation-specific results EMPTY | 药物刺激特异的结果为空 |
| Q05 | E | Perturb-seq base editing variant-to-function transcriptomic readout coding variants screen | ok | 正常 |
| Q06 | E | AlphaGenome Enformer Borzoi regulatory variant effect prediction personal genome expression | ok; whole-expression application to a personal genome not found | 正常；未找到对个人基因组整体表达的应用 |
| Q07 | E | chemCPA CPA GEARS scGPT drug perturbation prediction deep learning linear baseline critique benchmark | ok; chemCPA-specific critique thin | 正常；针对 chemCPA 的批评较少 |
| Q08 | E | Mendelian randomization genetically proxied drug target validation pharmacogenomics PharmGKB CPIC drug target variant database | MR ok; PharmGKB / CPIC EMPTY (filled by Q38) | MR 部分正常；PharmGKB / CPIC 为空（由 Q38 补上） |
| Q09 | S | world model latent dynamics Dreamer JEPA action-conditioned prediction architecture survey | ok | 正常 |
| Q10 | E | biologically informed neural network signaling pathway CellBox LEMBAS visible neural network P-NET mechanistic hybrid model | CellBox EMPTY | CellBox 为空 |
| Q11 | E | Tahoe-100M sci-Plex drug perturbation single-cell atlas cell line genotype context dependence LINCS L1000 | direct Tahoe versus LINCS comparison EMPTY | Tahoe 与 LINCS 的直接比较为空 |
| Q12 | E | genotype-aware perturbation response prediction model donor iPSC panel drug response variation transcriptome | EMPTY; nearest hits pertTF and P³ | 为空；最接近的命中是 pertTF 和 P³ |
| Q13 | E | resistance mutation EGFR BRAF kinase inhibitor transcriptional reprogramming adaptive signaling rewiring signature | ok | 正常 |
| Q14 | — | WebFetch of the arXiv abstract page for VCWorld | FAILED: DNS ENOTFOUND | 失败：DNS 解析失败（ENOTFOUND） |
| Q15 | — | Bash: query agent-proxy status with curl | BLOCKED by the permission classifier; not retried | 被权限分类器拦截；未重试 |
| Q16 | — | WebFetch of the Arc VCC 2025 wrap-up page | FAILED: DNS ENOTFOUND | 失败：DNS 解析失败（ENOTFOUND） |
| Q17 | E | gene-environment interaction eQTL treatment response glucocorticoid statin genotype by treatment interaction transcriptome | statin EMPTY | 他汀为空 |
| Q18 | E | Virtual Cell Challenge 2026 zero-shot generalization cellular contexts Cell paper benchmark design | ok | 正常 |
| Q19 | E | causal representation learning perturbation identifiability counterfactual single-cell interventions theory | counterfactual queries partly EMPTY | 反事实查询部分为空 |
| Q20 | E | DepMap GDSC PRISM cell line mutation drug sensitivity prediction transcriptome machine learning benchmark | ok | 正常 |
| Q21 | E | Open Targets OmniPath SIGNOR Reactome signaling network prior knowledge drug target pathway resource integration | joint pipeline of the four EMPTY | 四者联合管线为空 |
| Q22 | E | pharmacogenomic variants noncoding regulatory CYP2D6 star allele expression drug metabolism PharmVar annotation | noncoding regulatory annotation EMPTY | 非编码调控注释为空 |
| Q23 | E | "AI virtual cell" position paper Bunne Cell 2024 how to build virtual cell with AI roadmap universal representation | ok | 正常 |
| Q24 | E | transcriptome-wide association study drug response TWAS pharmacogenomics imputed expression clinical outcome | ok | 正常 |
| Q25 | E | CellFlow optimal transport flow matching cell state perturbation model single-cell trajectory | ok | 正常 |
| Q26 | E | mutation-conditioned genotype encoding perturbation response prediction cancer cell line encodings benchmark 2026 | ok | 正常 |
| Q27 | E | in silico perturbation variant aware foundation model drug target mutation predict expression change genotype conditioning | interrupted by the user; re-run in modified form as Q31 | 被用户中断；以改写形式作为 Q31 重跑 |
| Q28 | E | scPerturBench PerturBench evaluation metrics perturbation prediction pitfalls distribution shift E-distance | interrupted by the user; re-run in modified form as Q32 | 被用户中断；以改写形式作为 Q32 重跑 |
| Q29 | E | personal gene expression prediction from DNA sequence deep learning fails individual variation Enformer Basenji2 Sasse Huang Nature Genetics 2023 | ok; the author attribution in the query (Sasse, Huang) was not confirmed by the results | 正常；查询中的作者归属（Sasse、Huang）未被结果确认 |
| Q30 | E | response QTL drug exposure iPSC cardiomyocytes doxorubicin anthracycline statin lymphoblastoid cell lines gene expression response genotype | statin and lymphoblastoid-line hits EMPTY | 他汀与淋巴母细胞系的命中为空 |
| Q31 | E | genotype-conditioned single-cell foundation model variant effect cell-type-specific expression donor genotype input | EMPTY; nearest hit PertAdapt | 为空；最接近的命中是 PertAdapt |
| Q32 | S | PerturBench benchmark perturbation prediction evaluation metrics rank metrics mean baseline pitfalls | ok | 正常 |
| Q33 | E | Perturb-seq across genetically diverse donors iPSC lines genetic background modifies perturbation effect variant by perturbation interaction | human data EMPTY; yeast only | 人类数据为空；仅有酵母 |
| Q34 | E | predicting mutation effect on drug binding affinity resistance deep learning AlphaFold3 Boltz-2 protein-ligand variant | AF3 versus Boltz-2 head-to-head on resistance mutations EMPTY | AF3 与 Boltz-2 在耐药突变上的直接对比为空 |
| Q35 | S | LINCS L1000 connectivity map dataset size cell lines perturbagens Subramanian 2017 CMap | ok; exact cell-line count of the 2017 release not found | 正常；2017 年版本的确切细胞系数未找到 |
| Q36 | E | JEPA joint embedding predictive architecture single-cell gene expression perturbation latent prediction | ok | 正常 |
| Q37 | E | dynamic eQTL iPSC differentiation single-cell genetic effects change along trajectory Cuomo Jerber Strober | ok; involvement of Jerber and Strober (named in the query) not confirmed by the results | 正常；查询中提到的 Jerber 和 Strober 的参与未被结果确认 |
| Q38 | S | PharmGKB CPIC guidelines gene-drug pairs clinical annotations FDA table of pharmacogenomic biomarkers drug labeling | ok | 正常 |
| Q39 | S | AlphaMissense ESM1b EVE missense variant effect prediction benchmark deep mutational scanning ClinVar | EVE comparison EMPTY | 与 EVE 的比较为空 |
| Q40 | E | Arc Institute State model state transition embedding architecture perturbation prediction unseen cell contexts | ok | 正常 |
| Q41 | E | world model for biology perspective definition action-conditioned latent dynamics cell state counterfactual virtual cell versus conditional generative model | ok | 正常 |
| Q42 | E | ancestry bias eQTL reference panels European gene expression prediction portability diverse populations pharmacogenomics | pharmacogenomics angle EMPTY | 药物基因组学角度为空 |
| Q43 | E | drug-induced transcriptional response depends on mutation status BRAF KRAS TP53 cell lines pharmacotranscriptomics genotype-specific response | joint BRAF / KRAS / TP53 stratified study EMPTY | 联合 BRAF / KRAS / TP53 分层的研究为空 |
| Q44 | E | PRnet TranSiGen scGen predict transcriptional response unseen compounds L1000 generative model chemical structure | ok | 正常 |
<!-- search-table:end -->

## 4. Unmapped claims (F18) / 无法映射的主张（F18）

Three claims in search summaries could not be tied to a specific URL and are therefore not recorded as facts. Item a is a 51-person study of ethanol, caffeine and nicotine exposure that reported treatment-specific and temporally dynamic eQTLs. Item b is the statement that drug-response agreement between GDSC, CTRP and CCLE on one side and PRISM on the other stays low. Item c is a KRAS G12C mechanism in which a co-occurring PIK3CA mutation enables bypass signaling. Candidate sources for item b are [EV18, EV19], whose titles were truncated.

> 检索摘要中的三项主张无法对应到具体 URL，因此不记为事实。a 项是一项涉及 51 人、关于乙醇、咖啡因和尼古丁暴露的研究，报告了处理特异且随时间动态变化的 eQTL。b 项是关于 GDSC、CTRP 和 CCLE 与 PRISM 之间药物响应一致性仍然较低的说法。c 项是一个 KRAS G12C 机制，其中共存的 PIK3CA 突变使旁路信号成为可能。b 项的候选来源是 [EV18, EV19]，它们的标题被截断。

## 5. Topics that returned nothing / 没有返回结果的主题

The following topics returned no relevant hits, which is weak evidence of absence because the search tool is limited. Drug-stimulation-specific single-cell eQTLs (Q04). Statin studies in lymphoblastoid lines or hepatocytes (Q17, Q30). Human Perturb-seq across several donor genotypes with drugs (Q12, Q33). A model that takes inherited donor genotype as input (Q12, Q31). A direct comparison of Tahoe-100M with L1000 (Q11). CellBox (Q10). Counterfactual queries in causal representation learning (Q19). A joint pipeline of OmniPath, SIGNOR, Reactome and Open Targets (Q21). Noncoding regulatory annotation under PharmVar (Q22). A head-to-head comparison of AlphaFold 3 and Boltz-2 on resistance mutations (Q34). An EVE comparison with AlphaMissense and ESM1b (Q39). A pharmacogenomics-specific view of ancestry bias (Q42). A joint BRAF, KRAS and TP53 stratified pharmacotranscriptomic study (Q43).

> 下列主题没有返回相关命中，这只是缺失的弱证据，因为检索工具有限。药物刺激特异的单细胞 eQTL（Q04）。淋巴母细胞系或肝细胞中的他汀研究（Q17、Q30）。带药物的、跨多个供体基因型的人类 Perturb-seq（Q12、Q33）。以遗传性供体基因型为输入的模型（Q12、Q31）。Tahoe-100M 与 L1000 的直接比较（Q11）。CellBox（Q10）。因果表示学习中的反事实查询（Q19）。OmniPath、SIGNOR、Reactome 和 Open Targets 的联合管线（Q21）。PharmVar 下的非编码调控注释（Q22）。AlphaFold 3 与 Boltz-2 在耐药突变上的直接对比（Q34）。EVE 与 AlphaMissense 和 ESM1b 的比较（Q39）。祖源偏倚的药物基因组学视角（Q42）。BRAF、KRAS 和 TP53 联合分层的药物转录组研究（Q43）。

## 6. Failures and refusals / 失败与拒绝

Two page fetches failed because the hosts arxiv.org and arcinstitute.org could not be resolved (Q14, Q16), so the abstract of VCWorld and the Arc challenge wrap-up could not be read directly. One shell command that queried the agent proxy status was blocked by the permission classifier and was not retried (Q15). All bio-research literature servers (PubMed, bioRxiv, ChEMBL, Open Targets, Consensus and others) failed to connect with proxy 403 errors, so no structured literature or target-database query was possible. Two searches were interrupted by the user (Q27, Q28) and were re-run in modified form as Q31 and Q32.

> 两次页面抓取失败，因为无法解析 arxiv.org 和 arcinstitute.org 这两个主机（Q14、Q16），所以无法直接阅读 VCWorld 的摘要和 Arc 挑战赛总结。一条查询代理状态的 shell 命令被权限分类器拦截，未重试（Q15）。所有 bio-research 文献服务器（PubMed、bioRxiv、ChEMBL、Open Targets、Consensus 等）因代理 403 错误连接失败，因此无法进行结构化的文献或靶点数据库查询。两次检索被用户中断（Q27、Q28），并以改写形式重跑为 Q31 和 Q32。

## 7. Claims to verify first / 需要优先核验的主张

When full-text access is available, read the primary sources for the load-bearing claims first: [EV01, EV05, GV05, GV06, GV02, GD06, GD01, GD08, DS05, EV07, EV08, EV09, EV10, EV11, MD06, WM06, WM10, GV19, EV16, KB17]. For DS05, check the Tahoe-100M counts; for EV07 to EV11, check the 2026 challenge dates.

> 当可以获取全文时，首先阅读承重主张的原始来源：[EV01, EV05, GV05, GV06, GV02, GD06, GD01, GD08, DS05, EV07, EV08, EV09, EV10, EV11, MD06, WM06, WM10, GV19, EV16, KB17]。对于 DS05，核对 Tahoe-100M 的计数；对于 EV07 至 EV11，核对 2026 年挑战赛的日期。

Entries whose titles were truncated or whose metadata are missing, and which are flagged in the caveat columns of `data/sources.csv`, are [GD13, GD27, EV14, EV18, EV19, KB14].

> 标题被截断或元数据缺失、并在 `data/sources.csv` 的注意事项列中标注的条目是 [GD13, GD27, EV14, EV18, EV19, KB14]。

To enable full-text checking, the environment's network policy must allow outbound access: open the environment menu, choose Edit, go to Network access, and either pick a broader level or add the hosts under Allowed domains while leaving "Allow package managers" ticked. Suggested hosts are arxiv.org, biorxiv.org, nature.com, ncbi.nlm.nih.gov, cell.com, sciencedirect.com, elifesciences.org, journals.plos.org, github.com, arcinstitute.org, huggingface.co and virtualcellchallenge.org. The steps are at https://code.claude.com/docs/en/cloud-environments#network-access.

> 要启用全文核查，环境的网络策略必须允许出站访问：打开环境菜单，选择 Edit，进入 Network access，然后选择更宽的级别，或把这些主机加入 Allowed domains 并保持勾选 “Allow package managers”。建议的主机是 arxiv.org、biorxiv.org、nature.com、ncbi.nlm.nih.gov、cell.com、sciencedirect.com、elifesciences.org、journals.plos.org、github.com、arcinstitute.org、huggingface.co 和 virtualcellchallenge.org。步骤见 https://code.claude.com/docs/en/cloud-environments#network-access。

## 8. Leads for a second search round / 第二轮检索的线索

These leads come from background knowledge and were NOT retrieved in this session. They are unverified and must not be cited until they have been checked. Stimulus-response eQTL studies in immune cells (Fairfax 2014 in monocytes, Lee 2014 in dendritic cells, Kim-Hellmuth 2017, Alasoo 2018 in macrophages). A statin-treated lymphoblastoid-line eQTL study (Mangravite 2013). Multiplexed, donor-pooled single-cell RNA-seq with a stimulus (Kang 2018, interferon-beta in blood cells). Data details of GTEx, the eQTL Catalogue and OneK1K. Genome-scale Perturb-seq atlases (Replogle 2022 and later). DrugBank, DGIdb and ChEMBL. The primary JEPA papers. CellBox. The raw data of PharmGKB and CPIC. Multi-line work from the IGVF consortium.

> 这些线索来自背景知识，本次会话并未检索到。它们未经核验，在核实之前不得引用。免疫细胞中的刺激-响应 eQTL 研究（Fairfax 2014 单核细胞，Lee 2014 树突状细胞，Kim-Hellmuth 2017，Alasoo 2018 巨噬细胞）。他汀处理淋巴母细胞系的 eQTL 研究（Mangravite 2013）。带刺激的多路复用、供体混合单细胞 RNA-seq（Kang 2018，血细胞中的干扰素 β）。GTEx、eQTL Catalogue 和 OneK1K 的数据细节。基因组规模 Perturb-seq 图谱（Replogle 2022 及之后）。DrugBank、DGIdb 和 ChEMBL。JEPA 的原始论文。CellBox。PharmGKB 和 CPIC 的原始数据。IGVF 联盟的多细胞系工作。
